--- title: "Survodutide | PepTracker Pro" description: "A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Survodutide", "description": "A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026.", "url": "https://peptrackerpro.com/peptides/survodutide", "lastReviewed": "2026-07-02", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Survodutide", "item": "https://peptrackerpro.com/peptides/survodutide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People following dual agonist research?", "acceptedAnswer": { "@type": "Answer", "text": "Survodutide is a research peptide studied in preclinical models. A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026." } }, { "@type": "Question", "name": "Those interested in MASH/NAFLD treatments?", "acceptedAnswer": { "@type": "Answer", "text": "Survodutide is a research peptide studied in preclinical models. A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026." } }, { "@type": "Question", "name": "Individuals comparing metabolic peptide candidates?", "acceptedAnswer": { "@type": "Answer", "text": "Survodutide is a research peptide studied in preclinical models. A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Survodutide **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. Aliases BI 456906 Evidence Medium Evidence Last Updated 2026-07-02 Reading Time 3 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Proposed Mechanisms](#proposed-mechanisms) 4. [Evidence Snapshot](#evidence-snapshot) 5. [Commonly Discussed Benefits](#benefits) 6. [Safety & Cautions](#safety) 7. [Comparisons](#comparisons) 8. [Calculator Tools](#calculator) 9. [Citations](#citations) ## What It Is Survodutide (BI 456906) is a dual agonist targeting both GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. The glucagon receptor component increases energy expenditure and promotes hepatic fat oxidation, while GLP-1 reduces appetite — a complementary dual mechanism. In April 2026, Boehringer announced positive Phase 3 SYNCHRONIZE-1 topline results: adults with obesity or overweight (without T2D) achieved 16.6% mean weight loss at 76 weeks versus 3.2% with placebo, and 85.1% reached ≥5% body weight reduction. Statistically significant reductions in waist circumference — a marker of visceral fat and cardiometabolic risk — were also reported. Full SYNCHRONIZE-1 and SYNCHRONIZE-MASLD data were presented at the ADA 2026 Scientific Sessions in New Orleans (June 5–8), providing detailed efficacy breakdowns, cardiometabolic biomarker endpoints, and safety characterization that confirmed the topline 16.6% weight loss result. Results from the Phase 3 SYNCHRONIZE-2 (obesity with T2D) and SYNCHRONIZE-CVOT (cardiovascular outcomes) trials are expected later in 2026. The LIVERAGE Phase 3 program in MASH is also enrolling. Survodutide's liver-targeted glucagon activity distinguishes it from pure GLP-1 agonists and positions it as a leading candidate in the MASH therapeutic space alongside pemvidutide. In the emerging competitive landscape, survodutide's 16.6% weight loss at 76 weeks in SYNCHRONIZE-1 positions it below tirzepatide and retatrutide for weight loss magnitude but its dual mechanism (GLP-1 + glucagon rather than GLP-1 + GIP) offers a differentiated approach — particularly for liver fat reduction in MASH, where glucagon-mediated hepatic fat oxidation is the key therapeutic advantage. The Phase 3 SYNCHRONIZE program includes both obesity (SYNCHRONIZE-1) and MASH-specific (SYNCHRONIZE-NASH) arms, making survodutide one of the only peptides pursuing simultaneous registration for both indications. In Phase 2 MASH data, survodutide demonstrated histological improvement in liver fibrosis and MASH resolution at rates significantly exceeding placebo, with substantial reductions in hepatic fat content. A 2026 Priority Review NDA filing with the FDA positions survodutide for potential approval as the first peptide therapy specifically indicated for MASH. Full SYNCHRONIZE-1 and SYNCHRONIZE-MASLD data are being presented at the ADA 2026 Scientific Sessions (June 5–8, New Orleans), providing detailed efficacy breakdowns, cardiometabolic biomarker endpoints, and safety characterization confirming the 16.6% vs 3.2% placebo topline result. The Phase 3 LIVERAGE trial in MASH with fibrosis stages 2-3 and LIVERAGE-Cirrhosis trial in compensated MASH cirrhosis (stage 4) continue enrolling, with readouts expected later in 2026. These MASH-specific Phase 3 data will be critical for the anticipated NDA filing for MASH indication, building on the February 2026 Priority Review NDA filing for obesity. Also known as: BI 456906 ## Regulatory Status Priority Review NDA — Pre-Approval NDA filed under Priority Review in February 2026 for obesity indication; FDA decision expected Q3 2026. FDA Breakthrough Therapy designation granted for MASH (non-cirrhotic, fibrosis stages 2–3). Full Phase 3 SYNCHRONIZE-1 (obesity) and SYNCHRONIZE-MASLD data presented at ADA 2026 Scientific Sessions (June 5–8, 2026, New Orleans), confirming 16.6% weight loss topline result with detailed efficacy, biomarker, and safety characterization. Effective: February 2026 [View FDA Source](https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/results-phase-iii-synchronize-1-obesity-trial) ## Proposed Mechanisms - GLP-1 receptor agonism suppresses appetite and reduces caloric intake - Glucagon receptor activation increases hepatic energy expenditure and lipid oxidation - Dual mechanism promotes weight loss through both reduced intake and increased expenditure - Improves hepatic lipid metabolism, reducing liver fat accumulation - Enhances insulin sensitivity through combined metabolic pathway modulation ## Evidence Snapshot Medium Evidence Low Medium High Study Type Model Outcome Link Human (Phase 2) Adults with obesity, no T2D (n=387) Up to 18.7% weight loss at 46 weeks with 4.8mg dose [Source](https://pubmed.ncbi.nlm.nih.gov/38330987/) Human (Phase 2, NEJM) Adults with MASH and fibrosis (n=293) 62% MASH improvement at 4.8mg vs 14% placebo; ≥30% liver fat reduction in 67%; fibrosis improvement in 34–36% [Source](https://www.nejm.org/doi/full/10.1056/NEJMoa2401755) Human (Phase 3, SYNCHRONIZE-1) Adults with obesity/overweight without T2D (n=725, 14 countries) 16.6% mean weight loss with meaningful metabolic improvement; topline results April 2026 [Source](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement) Human (Phase 3, SYNCHRONIZE-1 topline) Adults with obesity/overweight without T2D (n=725, 14 countries), 76 weeks 16.6% mean weight loss vs 3.2% placebo; 85.1% achieved ≥5% loss; significant waist circumference reduction [Source](https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/results-phase-iii-synchronize-1-obesity-trial) Human (Phase 3, SYNCHRONIZE-1 — ADA 2026 full presentation confirmed) Adults with obesity/overweight without T2D — full data presentation Full efficacy breakdowns, cardiometabolic biomarker endpoints, and safety characterization to be presented at ADA 2026 (June 5-8); LIVERAGE MASH Phase 3 trials enrolling with readouts expected H2 2026 [Source](https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/results-phase-iii-synchronize-1-obesity-trial) ## Commonly Discussed Benefits [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) Researching Survodutide ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=survodutide) ## Safety & Cautions - NDA filed February 2026 under Priority Review; FDA decision expected Q3 2026 at earliest - FDA Breakthrough Therapy designation granted for MASH (non-cirrhotic, fibrosis stages 2–3) - Gastrointestinal side effects reported in trials (nausea, vomiting) - Long-term cardiovascular safety data not yet available; SYNCHRONIZE-CVOT planned - Not yet FDA-approved; available only through clinical trial participation until approval ## Comparisons See how Survodutide compares to related peptides: [Survodutide vs Dapiglutide](/compare/survodutide-vs-dapiglutide) [Survodutide vs Efinopegdutide](/compare/survodutide-vs-efinopegdutide) [Survodutide vs Efocipegtrutide](/compare/survodutide-vs-efocipegtrutide) [Survodutide vs Efpeglenatide](/compare/survodutide-vs-efpeglenatide) [Survodutide vs Efruxifermin](/compare/survodutide-vs-efruxifermin) [Survodutide vs Glepaglutide](/compare/survodutide-vs-glepaglutide) [Survodutide vs Maridebart Cafraglutide (MariTide)](/compare/survodutide-vs-maridebart-cafraglutide) [Survodutide vs MariTide](/compare/survodutide-vs-maritide) [Survodutide vs Mazdutide](/compare/survodutide-vs-mazdutide) [Survodutide vs NA-931 (Bioglutide)](/compare/survodutide-vs-na-931) [Survodutide vs Pegozafermin](/compare/survodutide-vs-pegozafermin) [Survodutide vs Retatrutide](/compare/survodutide-vs-retatrutide) [Survodutide vs Semaglutide](/compare/survodutide-vs-semaglutide) [Survodutide vs Tirzepatide](/compare/survodutide-vs-tirzepatide) [Survodutide vs UBT251](/compare/survodutide-vs-ubt251) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Survodutide Phase 2 MASH trial — NEJM 2024 [PubMed](https://www.nejm.org/doi/full/10.1056/NEJMoa2401755) 2. \[2\] Survodutide Phase 2 obesity trial — Lancet 2024 [PubMed](https://pubmed.ncbi.nlm.nih.gov/38330987/) 3. \[3\] SYNCHRONIZE-2 baseline characteristics — Diabetes Obes Metab 2026 [PubMed](https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70263) 4. \[4\] SYNCHRONIZE-1 baseline characteristics — PubMed 2026 [PubMed](https://pubmed.ncbi.nlm.nih.gov/41187967/) 5. \[5\] Boehringer Ingelheim — SYNCHRONIZE-1 Phase 3 topline results, April 2026 [PubMed](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement) 6. \[6\] FDA Grants Survodutide Breakthrough Therapy Designation for MASH — Pharmacy Times 2026 [PubMed](https://www.pharmacytimes.com/view/fda-grants-survodutide-breakthrough-therapy-designation-for-treatment-of-adults-with-mash) 7. \[7\] Boehringer Ingelheim — Phase III SYNCHRONIZE-1 topline results. April 28, 2026 [PubMed](https://www.globenewswire.com/news-release/2026/04/28/3282218/0/en/boehringer-ingelheim-s-novel-glucagon-glp-1-dual-agonist-survodutide-achieved-significant-weight-loss-of-16-6-delivering-meaningful-metabolic-improvement-in-people-with-obesity-or-.html) ### Keep researching in the app - Log Survodutide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=survodutide) [Browse more peptides](/peptides) ## Related Peptides ### Dapiglutide Medium Evidence A long-acting, once-weekly dual GLP-1 and GLP-2 receptor agonist peptide (Zealand Pharma) developed for obesity, uniquely pairing GLP-1-driven weight loss with GLP-2 activation intended to improve intestinal barrier function and reduce obesity-related low-grade inflammation; development was paused in November 2025. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Gut Health](/benefits/gut-health)[Inflammation](/benefits/inflammation) [View Details](/peptides/dapiglutide) [\+ Compare](/compare?select=dapiglutide)[](https://app.peptrackerpro.com/?add=dapiglutide) ### Efinopegdutide Medium Evidence Efinopegdutide (MK-6024, formerly HM12525A and JNJ-64565111) is an investigational once-weekly subcutaneous dual agonist of the GLP-1 and glucagon receptors being developed by Merck for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease. It is a synthetic oxyntomodulin-based peptide - a modified GLP-1/glucagon dual-agonist sequence conjugated to a human IgG4 Fc fragment through a 10 kDa polyethylene glycol linker using Hanmi Pharmaceutical's LAPSCovery half-life-extension platform, which stretches dosing to once weekly. The design pairs the GLP-1 arm (appetite suppression, glycemic control, weight loss) with a glucagon arm that raises energy expenditure and acts directly on the liver to burn hepatic fat - the feature that sets it apart from pure GLP-1 drugs. In the head-to-head Phase 2a trial in NAFLD (Journal of Hepatology, 2023), efinopegdutide 10 mg cut liver fat content by 72.7% at 24 weeks versus 42.3% for semaglutide 1 mg, with two-thirds of efinopegdutide recipients falling below the 5% liver-fat threshold that defines a normal liver. Merck holds FDA Fast Track designation for the MASH program and is running Phase 2b studies plus a dedicated trial in compensated cirrhosis due to steatohepatitis; the earlier type 2 diabetes and obesity indications were discontinued in favor of the liver focus. [metabolic-health](/benefits/metabolic-health)[Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[disease-modification](/benefits/disease-modification)+1 more [View Details](/peptides/efinopegdutide) [\+ Compare](/compare?select=efinopegdutide)[](https://app.peptrackerpro.com/?add=efinopegdutide) ### Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. [Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[Glycemic Control](/benefits/glycemic-control)[Metabolism](/benefits/metabolism) [View Details](/peptides/efocipegtrutide) [\+ Compare](/compare?select=efocipegtrutide)[](https://app.peptrackerpro.com/?add=efocipegtrutide) ### Efpeglenatide Low Evidence A once-weekly, long-acting GLP-1 receptor agonist from Hanmi Pharmaceutical built on a different molecular backbone than semaglutide or liraglutide: instead of a modified human GLP-1, efpeglenatide uses exendin-4 - the naturally DPP-4-resistant GLP-1 mimic first found in Gila monster venom - fused to a fragment of a human antibody (an IgG4 Fc) through a small polyethylene-glycol (mini-PEG) linker using Hanmi's LAPSCOVERY half-life-extension platform. That design lets one subcutaneous injection lower blood sugar, curb appetite and reduce body weight for a full week. Efpeglenatide is best known for the landmark AMPLITUDE-O cardiovascular outcomes trial (NEJM 2021), in which 4,076 people with type 2 diabetes and cardiovascular or kidney disease had a 27% lower rate of major adverse cardiovascular events (MACE hazard ratio 0.73) and a 32% lower rate of a composite kidney outcome (hazard ratio 0.68) versus placebo - the first cardiovascular outcomes win for an exendin-based GLP-1 and one of the clearest kidney signals in the class, with benefit seen regardless of whether patients were also taking an SGLT2 inhibitor. Originally licensed to Sanofi and then returned to Hanmi in 2020, efpeglenatide is now being advanced primarily for obesity and overweight, with a Phase 3 program that has completed enrollment and a targeted first launch in South Korea in the second half of 2026. It is an investigational (not yet approved) prescription medicine, not a supplement or research chemical. [weight-loss](/benefits/weight-loss)[blood-sugar](/benefits/blood-sugar)[Cardiovascular](/benefits/cardiovascular)[kidney](/benefits/kidney) [View Details](/peptides/efpeglenatide) [\+ Compare](/compare?select=efpeglenatide)[](https://app.peptrackerpro.com/?add=efpeglenatide) ### Efruxifermin Low Evidence Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026). [metabolic dysfunction-associated steatohepatitis (MASH/NASH) - fibrosis improvement and MASH resolution in pre-cirrhotic F2-F3 disease (investigational)]()[reversal of compensated (F4) cirrhosis due to MASH without worsening of MASH (investigational; Phase 2b SYMMETRY, Phase 3 SYNCHRONY Outcomes)]()[reductions in liver fat (MRI-PDFF), liver enzymes, and non-invasive fibrosis biomarkers]()[improved insulin sensitivity, glycemic markers, and blood lipids (lower triglycerides, improved cholesterol profile)]()+1 more [View Details](/peptides/efruxifermin) [\+ Compare](/compare?select=efruxifermin)[](https://app.peptrackerpro.com/?add=efruxifermin) ### Glepaglutide Medium Evidence A long-acting glucagon-like peptide-2 (GLP-2) analog given by once- or twice-weekly subcutaneous injection that helps the gut absorb more nutrients in short bowel syndrome, reducing dependence on IV (parenteral) nutrition. [intestinal absorption]()[short bowel syndrome]()[reduced parenteral support]() [View Details](/peptides/glepaglutide) [\+ Compare](/compare?select=glepaglutide)[](https://app.peptrackerpro.com/?add=glepaglutide) ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/maridebart-cafraglutide) [\+ Compare](/compare?select=maridebart-cafraglutide)[](https://app.peptrackerpro.com/?add=maridebart-cafraglutide) ### MariTide High Evidence A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/maritide) [\+ Compare](/compare?select=maritide)[](https://app.peptrackerpro.com/?add=maritide) ### Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/mazdutide) [\+ Compare](/compare?select=mazdutide)[](https://app.peptrackerpro.com/?add=mazdutide) ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/na-931) [\+ Compare](/compare?select=na-931)[](https://app.peptrackerpro.com/?add=na-931) ### Pegozafermin Low Evidence Pegozafermin (development code BIO89-100) is an investigational, long-acting analog of fibroblast growth factor 21 (FGF21) being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and for severe hypertriglyceridemia (SHTG). Originally developed by 89bio and acquired by Roche in a deal announced in September 2025 (about $2.4 billion upfront and up to roughly $3.5 billion including a contingent value right), it uses site-specific glycoPEGylation to extend the very short half-life of native FGF21 to roughly 55-100 hours, enabling once-weekly or once-every-two-weeks subcutaneous dosing. FGF21 is a metabolic hormone that acts on liver, fat, and other tissues to improve insulin sensitivity, lower triglycerides, and exert direct anti-fibrotic and anti-inflammatory effects. In the Phase 2b ENLIVEN trial in biopsy-confirmed F2-F3 MASH, the 44 mg every-two-weeks dose produced at least a one-stage fibrosis improvement without worsening of MASH in about 27% of patients versus 7% on placebo, and MASH resolution without worsening of fibrosis in about 26% versus 2% on placebo, with benefits sustained through week 48. Pegozafermin holds FDA Breakthrough Therapy designation and EMA PRIME status for MASH and has advanced into the Phase 3 ENLIGHTEN program (ENLIGHTEN-Fibrosis in non-cirrhotic F2-F3 MASH and ENLIGHTEN-Cirrhosis in compensated F4 cirrhosis), plus the Phase 3 ENTRUST trial in SHTG. [metabolic dysfunction-associated steatohepatitis (MASH/NASH) - fibrosis improvement, MASH resolution, and reduced liver fat (investigational)]()[severe hypertriglyceridemia (SHTG) - large reductions in blood triglycerides (investigational; Phase 3 ENTRUST)]()[improved insulin sensitivity and glycemic markers]()[improvements in non-invasive markers of liver injury and fibrosis (liver fat by MRI-PDFF, liver enzymes, fibrosis biomarkers)]()+1 more [View Details](/peptides/pegozafermin) [\+ Compare](/compare?select=pegozafermin)[](https://app.peptrackerpro.com/?add=pegozafermin) ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/retatrutide) [\+ Compare](/compare?select=retatrutide)[](https://app.peptrackerpro.com/?add=retatrutide) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation) [View Details](/peptides/ubt251) [\+ Compare](/compare?select=ubt251)[](https://app.peptrackerpro.com/?add=ubt251) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.